



IWSF.405.17.2022.IP.1
WTC/0105_02_04/31

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC as amended

Chief Pharmaceutical Inspector

/the Competent Authority of Poland/

confirms the following:

the manufacturer

Zakłady Farmaceutyczne Polpharma S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański, POLAND

site address

Zakłady Farmaceutyczne Polpharma S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański, POLAND


has been inspected under the national inspection programme in connection with manufacturing authorisation No. **040/0105/15** in accordance with Art. 40 of Directive 2001/83/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2021, item 1977 as amended)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **26-29/10/2021**, it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.



Part 2

Human Medicinal Products

1 MANUFACTURING OPERATIONS	
1.1	Sterile Products
	<p>1.1.1 Aseptically prepared</p> <p>1.1.1.1 Large volume liquids</p> <p>1.1.1.4 Small volume liquids</p> <p>1.1.2 Terminally sterilised</p> <p>1.1.2.3 Small volume liquids</p> <p>1.1.3 Batch certification</p>
1.5	Packaging
	1.5.2 Secondary packing
1.6	Quality control testing
	<p>1.6.1 Microbiological: sterility</p> <p>1.6.3 Chemical/Physical</p> <p>1.6.4 Biological</p>


Any restrictions or clarifying remarks related to the scope of this certificate:

Points: 1.1.1.1, 1.1.1.4, 1.1.2.3 concerns products manufactured from highly sensitizing materials.

Point 1.1.1.4, 1.1.2.3 concerns products manufactured from teratogenic materials and highly toxic materials.

This certificate should not be relied upon to reflect the compliance status if more than 30 months have elapsed since the date of the inspection.

The certificate was issued on the basis of a partially remote inspection.



On the Chief Pharmaceutical Inspector authority

Marcin Wójtowicz
Marcin Wójtowicz
 Director General